EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)

Inclusion Criteria for Observation Phase:

- Voluntarily sign and date an informed consent agreement

- Have participated in and completed the double-blind study EN3835-201

- Be willing to apply sunscreen to any treated quadrant before each exposure to sun

Inclusion Criteria for Treatment Phase:

- Voluntarily sign and date an informed consent agreement

- Have participated in and completed the double-blind study EN3835-201

- Be willing to apply sunscreen to any treated quadrant before each exposure to sun

- Have at least 1 quadrant with: a score of 3 or 4 (moderate or severe) as reported on
the PCSS (Photonumeric Cellulite Severity Scale) by the subject or investigator, and a
Hexsel CSS (Cellulite Severity Scale) score no greater than 13

- Be judged to be in good health

- Have a negative urine pregnancy test at screening and be using an effective
contraception method, be surgically sterile, or post-menopausal

Exclusion Criteria for Observation Phase:

Exclusion Criteria for Treatment Phase:

- Has used, or intends to use during the course of the study, other treatment of EFP on
the legs or buttocks

- Is presently nursing a baby or providing breast milk for a baby

- Intends to become pregnant during the study

- Currently receiving, has received within 7 days before injection of study drug, or
plans to receive an anticoagulant or antiplatelet medication

- History of stroke or bleeding